DiaMedica Therapeutics Inc. DMAC
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
DiaMedica Therapeutics Inc. (DMAC) is a healthcare company listed in the US with a market value of about $474M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -38%.
About DiaMedica Therapeutics
DiaMedica Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. It was profitable in 0 of the last 9 years in our data. Its share count rose by 78% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $500000 | — |
| Net income | -$33M | -$24M | -$19M | -$14M | -$14M | -$12M | -$11M | -$6M | -$4M |
| Free cash flow | -$29M | -$22M | -$19M | -$12M | -$12M | -$9M | -$9M | -$6M | -$4M |
| EPS (diluted) | $-0.70 | $-0.60 | $-0.60 | $-0.52 | $-0.65 | $-0.78 | $-0.89 | $-0.74 | $-0.72 |
| Net margin | — | — | — | — | — | — | — | -1146.8% | — |
| ROIC | -48.2% | -51.4% | -32.6% | -34.3% | -24.5% | -38.4% | -117.8% | -31.4% | -446.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $15.50, 76% above the current price; targets range from $11.00 to $25.00; the consensus rating is “Strong buy”; expected EPS is $-0.79 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does DiaMedica Therapeutics pay a dividend?
Not currently.
Is DiaMedica Therapeutics a good stock to buy?
We do not give buy or sell advice. DiaMedica Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.